The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies.
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; NGM Biopharmaceuticals; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Jose Pacheco
No Relationships to Disclose
 
Sreenivasa Chandana
Leadership - The Cancer & Hematology Centers
Consulting or Advisory Role - AstraZeneca; IPSEN; Novocure
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); BioNTech SE (Inst); BMS (Inst); Cardiff Oncology (Inst); Chugai Pharma (Inst); Corcept Therapeutics (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Exelixis (Inst); Genentech/Roche (Inst); Halda Therapeutics (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Johnson & Johnson/Janssen (Inst); Medlink (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Rondo Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
 
Hristina Pashova
Employment - Corcept Therapeutics
Stock and Other Ownership Interests - Corcept Therapeutics
 
Camille Renard
Employment - Alphabet (I); Corcept Therapeutics; Gilead Sciences; Obsidian Therapeutics
Stock and Other Ownership Interests - Alphabet (I); Gilead Sciences; Obsidian Therapeutics
 
Priya Choudhry
Employment - Corcept Therapeutics
Stock and Other Ownership Interests - Corcept Therapeutics; United Health Group; Viking Therapeutics
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Katherine Kurnit
Honoraria - OncLive/MJH Life Sciences
Travel, Accommodations, Expenses - GOG Partners
 
Drew Rasco
Research Funding - 23andMe (Inst); Adcentrx Therapeutics (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Aulos Bioscience (Inst); Avenzo (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Context Therapeutics (Inst); Corcept Therapeutics (Inst); Cullinan Oncology (Inst); Eikon Therapeutics (Inst); Flare Therapeutics (Inst); FoRx Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Macrogenics (Inst); MediLink Therapeutics (Inst); Multitude Therapeutics (Inst); OnCusp Therapeutics (Inst); PAQ Therapeutics (Inst); Plexium (Inst); PureTech (Inst); Rondo (Inst); Takeda (Inst); TD2 (Inst); Whitehawk (Inst); Whitehawk (Inst)